Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
Key Highlights
- ➤Pooled ARROW/TAPISTRY analysis showed 53% overall response across 49 RET fusion-positive solid-tumor patients
- ➤Previously treated pancreatic tumors achieved 88% overall response rate, or 7 of 8 patients
- ➤TAPISTRY thyroid-cancer cohort delivered 81.3% overall response among 16 evaluable patients
- ➤First-line pralsetinib produced 75% response versus 26% for prior standard therapies in RET-positive NSCLC
- ➤First-line pralsetinib patients had longer progression, discontinuation, and next-treatment-or-death times
- ➤At Cycle 12 Day 1, at least 75% of evaluable NSCLC patients had improved or stable quality-of-life scores
Expert Statements
Alison L. Hannah, Chief Medical Officer of Rigel Pharmaceuticals
“These analyses reinforce the breadth of evidence supporting pralsetinib across RET fusion-positive cancers and provide important new insights into its clinical activity, durability and impact on patients”
Alison L. Hannah, Chief Medical Officer of Rigel Pharmaceuticals
“We are particularly encouraged by the findings across multiple solid tumor types, as well as the first-line clinical outcomes and quality-of-life data in RET fusion-positive NSCLC, which further our understanding of the potential role of pralsetinib for patients whose tumors are driven by RET fusions.”
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026 PR Newswire
* Pooled ARROW and TAPISTRY analysis demonstrated a 53% overall response rate in patients with RET fusion-positive solid tumors * Additional analyses highlight first-line clinical outcomes and patient-reported quality of life in RET fusion-positive NSCLC and efficacy and safety in RET fusion-positive thyroid cancer SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced analysis of the pooled efficacy and safety data from two clinical trials of GAVRETO(® )(pralsetinib), ARROW (NCT03037385) and TAPISTRY (NCT04589845), in patients with rearranged during transfection (RET) fusion-positive solid tumors will be presented in a rapid oral session at the European Society For Medical Oncology (ESMO) Congress 2026 on Sunday, October 25, 2026.
Get started
Create a free account to read the full story.